In8bio Inc Stock Today
| INAB Stock | USD 2.09 0.04 1.88% |
PerformanceVery Weak
| Odds Of DistressVery High
|
In8bio is trading at 2.09 as of the 1st of July 2025, a 1.88 percent decrease since the beginning of the trading day. The stock's open price was 2.13. In8bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 2nd of April 2025 and ending today, the 1st of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. The company has 3.44 M outstanding shares of which 243.29 K shares are currently shorted by private and institutional investors with about 0.66 trading days to cover. More on In8bio Inc
Moving together with In8bio Stock
| 0.86 | VALN | Valneva SE ADR | PairCorr |
| 0.62 | ERNA | Eterna Therapeutics | PairCorr |
| 0.8 | XAGE | Longevity Health Hol Symbol Change | PairCorr |
Moving against In8bio Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
In8bio Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsIn8bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand In8bio's financial leverage. It provides some insight into what part of In8bio's total assets is financed by creditors.
| |||||
In8bio Inc (INAB) is traded on NASDAQ Exchange in USA. It is located in 350 5th Avenue, New York, NY, United States, 10118 and employs 18 people. In8bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.2 M. In8bio Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.44 M outstanding shares of which 243.29 K shares are currently shorted by private and institutional investors with about 0.66 trading days to cover.
In8bio Inc currently holds about 25.74 M in cash with (24.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37.
Check In8bio Probability Of Bankruptcy
Ownership AllocationIn8bio owns 4.0 % of its outstanding shares held by insiders and 20.98 % owned by institutions.
Check In8bio Ownership Details
In8bio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2025-03-31 | 58.5 K | |
| Two Sigma Securities, Llc | 2025-03-31 | 34.3 K | |
| Overbrook Management Corp | 2025-03-31 | 33.8 K | |
| Citadel Advisors Llc | 2025-03-31 | 29.4 K | |
| Susquehanna International Group, Llp | 2025-03-31 | 24.8 K | |
| Tower Research Capital Llc | 2025-03-31 | 20.3 K | |
| Capital Investment Advisory Services, Llc | 2025-03-31 | 17.6 K | |
| Virtu Financial Llc | 2025-03-31 | 15.1 K | |
| Ubs Group Ag | 2025-03-31 | 12.3 K | |
| Bios Capital Management, Lp | 2025-03-31 | 8.6 M | |
| Franklin Resources Inc | 2025-03-31 | 5.7 M |
In8bio Historical Income Statement
In8bio Stock Against Markets
In8bio Corporate Management
| Pharm MPH | VP Communications | Profile | |
| TaiWei Ho | President, CoFounder | Profile | |
| William Ho | President, CoFounder | Profile | |
| Trishna MD | Chief Officer | Profile | |
| Kate Rochlin | Chief Officer | Profile | |
| Lawrence Lamb | CoFounder VP | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in In8bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In8bio. If investors know In8bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In8bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of In8bio Inc is measured differently than its book value, which is the value of In8bio that is recorded on the company's balance sheet. Investors also form their own opinion of In8bio's value that differs from its market value or its book value, called intrinsic value, which is In8bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In8bio's market value can be influenced by many factors that don't directly affect In8bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In8bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if In8bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In8bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.